BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 26393585)

  • 1. The Use of a Liposomal Formulation Incorporating an Antimicrobial Peptide from Tilapia as a New Adjuvant to Epirubicin in Human Squamous Cell Carcinoma and Pluripotent Testicular Embryonic Carcinoma Cells.
    Lo YL; Lee HP; Tu WC
    Int J Mol Sci; 2015 Sep; 16(9):22711-34. PubMed ID: 26393585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cationic PEGylated liposomes incorporating an antimicrobial peptide tilapia hepcidin 2-3: an adjuvant of epirubicin to overcome multidrug resistance in cervical cancer cells.
    Juang V; Lee HP; Lin AM; Lo YL
    Int J Nanomedicine; 2016; 11():6047-6064. PubMed ID: 27895479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-encapsulation of chrysophsin-1 and epirubicin in PEGylated liposomes circumvents multidrug resistance in HeLa cells.
    Lo YL; Tu WC
    Chem Biol Interact; 2015 Dec; 242():13-23. PubMed ID: 26335193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formononetin potentiates epirubicin-induced apoptosis via ROS production in HeLa cells in vitro.
    Lo YL; Wang W
    Chem Biol Interact; 2013 Oct; 205(3):188-97. PubMed ID: 23867903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo.
    Lo YL; Liu Y; Tsai JC
    Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of the mRNA-binding protein HuR as a novel reversal mechanism of epirubicin-triggered multidrug resistance in colorectal cancer cells.
    Lin GL; Ting HJ; Tseng TC; Juang V; Lo YL
    PLoS One; 2017; 12(10):e0185625. PubMed ID: 28968471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 7,3',4'-Trihydroxyisoflavone modulates multidrug resistance transporters and induces apoptosis via production of reactive oxygen species.
    Lo YL; Wang W; Ho CT
    Toxicology; 2012 Dec; 302(2-3):221-32. PubMed ID: 22914566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides.
    Lo YL; Liu Y
    PLoS One; 2014; 9(3):e90180. PubMed ID: 24637737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibit multidrug resistance and induce apoptosis by using glycocholic acid and epirubicin.
    Lo YL; Ho CT; Tsai FL
    Eur J Pharm Sci; 2008 Sep; 35(1-2):52-67. PubMed ID: 18606222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer.
    Zhao YZ; Dai DD; Lu CT; Chen LJ; Lin M; Shen XT; Li XK; Zhang M; Jiang X; Jin RR; Li X; Lv HF; Cai L; Huang PT
    Cancer Lett; 2013 Mar; 330(1):74-83. PubMed ID: 23186833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of multidrug resistance to epirubicin by cyclosporin A in liposomes or intralipid.
    Lo YL; Liu FI; Yang JM; Cherng JY
    Anticancer Res; 2001; 21(1A):445-50. PubMed ID: 11299776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glaucarubinone sensitizes KB cells to paclitaxel by inhibiting ABC transporters via ROS-dependent and p53-mediated activation of apoptotic signaling pathways.
    Karthikeyan S; Hoti SL; Nazeer Y; Hegde HV
    Oncotarget; 2016 Jul; 7(27):42353-42373. PubMed ID: 27304668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A potential daidzein derivative enhances cytotoxicity of epirubicin on human colon adenocarcinoma Caco-2 cells.
    Lo YL
    Int J Mol Sci; 2012 Dec; 14(1):158-76. PubMed ID: 23344026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of functional epirubicin liposomes to induce programmed death in refractory breast cancer.
    Liu L; Mu LM; Yan Y; Wu JS; Hu YJ; Bu YZ; Zhang JY; Liu R; Li XQ; Lu WL
    Int J Nanomedicine; 2017; 12():4163-4176. PubMed ID: 28615943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals.
    Men Y; Wang XX; Li RJ; Zhang Y; Tian W; Yao HJ; Ju RJ; Ying X; Zhou J; Li N; Zhang L; Yu Y; Lu WL
    Int J Nanomedicine; 2011; 6():3125-37. PubMed ID: 22163164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The nuclear membrane in multidrug resistance: microinjection of epirubicin into bladder cancer cell lines.
    Featherstone JM; Speers AG; Lwaleed BA; Hayes MC; Cooper AJ; Birch BR
    BJU Int; 2005 May; 95(7):1091-8. PubMed ID: 15839939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of PSC 833 liposomes and Intralipid on the transport of epirubicin in Caco-2 cells and rat intestines.
    Lo Y; Liu F; Cherng J
    J Control Release; 2001 Sep; 76(1-2):1-10. PubMed ID: 11532308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Berberine promotes antiproliferative effects of epirubicin in T24 bladder cancer cells by enhancing apoptosis and cell cycle arrest
.
    Zhuo Y; Chen Q; Chen B; Zhan X; Qin X; Huang J; Lv X
    Int J Clin Pharmacol Ther; 2017 Jan; 55(1):32-40. PubMed ID: 27719740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133+ cancer stem-like cells.
    Yang Q; Zhang T; Wang C; Jiao J; Li J; Deng Y
    Eur J Pharm Biopharm; 2014 Nov; 88(3):737-45. PubMed ID: 25460146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.